Home / Aprepitant / Norway
NO ATC A04AD12 · updated 2 Nov 2026
Aprepitant shortage in Norway
Is there an Aprepitant shortage in Norway?
Yes. As of 2 Nov 2026, 2 Aprepitant products are reported short in Norway, the first since 28 Feb 2025. The company estimate for the return is 31 Jan 2028. Main reason: commercial decision or withdrawal.
Also short in United States, Canada, Germany, France, Italy, Spain, Ireland, Austria, Czechia, Sweden, Australia. All countries.
Affected products in Norway
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| NO | Ivemend 150 mg pulver til infusjonsvæske, oppløsning, 150 mg hetteglass | Merck Sharp & Dohme B.V. | 28 Feb 2025 | 31 Jan 2028 | Commercial decision or withdrawal Kommersielle grunner |
| NO | Emend 125 mg kapsel, hard, 5 x 1 stk endoseblisterpakning anticipated | Merck Sharp & Dohme B.V. (1) | 15 Mar 2027 | 31 Jan 2028 | Increased demand Uventet økt etterspørsel |
Source
DMP (Norwegian Medical Products Agency). Official list. Ongoing and announced shortages reported by companies; one row per pack (varenummer).